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Abstract  
Huntington disease-like 2 (HDL2) and Huntington disease (HD) are adult-onset 
neurodegenerative diseases characterized by movement disorders, psychiatric disturbances and 
cognitive decline. Brain tissue from HD and HDL2 patients show degeneration of the striatum 
and ubiquitinated inclusions immunoreactive for polyglutamine (polyQ) antibodies. Despite 
these similarities, the diseases result from different genetic mutations. HD is caused by a CAG 
repeat expansion in the huntingtin (HTT) gene, while HDL2 results from expansion at 
the junctophilin 3 locus. Recent evidence indicates the HDL2 expansion may give rise to a toxic 
polyQ protein transcribed from an antisense mRNA derived from the junctophilin locus. To 
investigate this hypothesis, we generated and characterized a Drosophila HDL2 model and 
compared it to a previously established HD model. We find that neuronal expression of HDL2-
Q15 is not toxic, while expression of an expanded HDL2-Q138 protein is lethal. HDL2-Q138 
forms large nuclear aggregates, with only smaller puncta observed in the cytoplasm. This is in 
contrast to what is observed in a Drosophila model of HD, where polyQ aggregates localize 
exclusively to the cytoplasm. Altering localization of HLD2 with the addition of a nuclear 
localization or nuclear export sequence demonstrates nuclear accumulation is required for 
toxicity in the Drosophila HDL2 model. Directing HDL2-Q138 to the nucleus exacerbates 
toxicity in multiple tissue types, while confining HDL2-Q138 to the cytoplasm restores viability 
to control levels. We conclude that while HD and HDL2 have similar clinical profiles, distinct 
pathogenic mechanisms are likely to drive toxicity in Drosophila models of these disorders. 
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Introduction 
 Huntington disease like 2 (HDL2) is an autosomal dominant neurodegenerative disorder 
with symptoms and neuropathology strikingly similar to Huntington disease (HD) (1). Symptoms 
include chorea, psychiatric disturbances and cognitive decline with death resulting 
approximately 15 years after onset (2). Patients’ brains show extensive degeneration of the 
caudate nucleus and cortical thinning (2). Ubiquitinated intranuclear inclusions that stain with 
1C2, an antibody that detects polyglutamine (polyQ) proteins, are a hallmark of the disorder (2). 
In spite of symptomatic and neuropathological similarities to HD, HDL2 patients do not have a 
mutation in the huntingtin (HTT) gene. The HDL2 mutation results from a CTG/CAG 
trinucleotide repeat expansion at the junctophilin 3 locus on chromosome 16 (3). As with HD, 
the number of tandem repeats varies among healthy individuals; in both HD and HDL2, the 
disease state results from expansions greater than approximately 40 repeats. Depending on the 
frame, the mutation in HDL2 could result in a polyleucine expansion, a polyalanine expansion, 
or an expansion in the 3’ UTR (3). However, expanded polyalanine or polyleucine proteins have 
not been detected in HDL2 patient brain samples (4).  
 Several mechanisms of toxicity have been proposed to contribute to HDL2 pathogenesis.  
First, the expansion may impair transcription of JPH3, leading to a loss of function (4). Another 
potential pathogenic pathway is RNA toxicity from expanded CUG transcripts. Expanded CUG 
transcripts have been shown to cause toxicity in several diseases, including Machado-Joseph 
disease (MJD), spinocerebellar ataxia 8 (SCA8), and myotonic dystrophy 1 (DM1) (5–7). CUG 
RNA foci have been found in postmortem HDL2 patient brain tissue, and staining indicates the 
RNA splicing protein muscleblind is sequestered in these foci (8). While CUG RNA toxicity 
may contribute to HDL2 pathogenesis, it does not explain the existence of ubiquitinated 
aggregates in patients’ brains. Protein aggregates and RNA foci rarely, if ever, co-localize (2), 
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suggesting protein aggregates may be the result of a separate pathogenic pathway.  
 Recently, toxicity in microsatellite expansion diseases has been suggested to occur from 
transcripts originating in both sense and antisense directions. Pathology resulting from 
bidirectional transcription has been described in several CTG expansion diseases, including 
SCA8, HDL2 (9–11), and others (11). Antisense transcription across the CTG expansion in 
JPH3 results in an expanded CAG transcript, which, if translated, produces a novel polyQ 
protein. Several lines of evidence support a polyQ pathology model in HDL2. First, the presence 
of an active promoter on the antisense strand is supported by bioinformatics and confirmed 
experimentally using luciferase reporter assays (4, 10). Bidirectional transcription across the 
JPH3 locus has also been demonstrated by the presence of expanded CAG transcripts in a BAC 
HDL2 mouse model (10). Experiments in postmortem human tissue reveal the presence of an 
antisense CAG transcript (4). Importantly, in HDL2 patient brain tissue, immunohistochemistry 
has demonstrated 1C2-positive intranuclear inclusions in HDL2 patients’ motor cortex and 
amygdala (2). Evidence of polyQ protein production has also been found in the HDL2 mouse 
model using the polyQ antibodies 1C2 and 3B5H10 (10). Further support for the role of an 
antisense transcript comes from sequencing the sense and antisense transcriptomes of human 
cells (12). Of the 10,000 genes analyzed, most demonstrated transcription primarily in the sense 
orientation, while a small subset demonstrated significant transcriptional activity in both 
directions. Fewer than 2.5% of genes were classified as primarily antisense. Transcription at 
JPH3 falls into the last, rare category. 
 To investigate how an HDL2 polyQ protein may exert toxicity, we generated transgenic 
Drosophila harboring the human antisense HDL2-CAG transcript. We compared mechanisms of 
toxicity to those observed in a Huntington Disease Drosophila model we previously generated, 
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or in Drosophila expressing a pure polyQ tract. Despite the similar neuropathology between HD 
and HDL2 patients, we observe that the polyQ proteins promote toxicity through localization in 
different subcellular compartments in Drosophila neurons. The HDL2 polyQ protein is also 
distinct from a pure polyQ tract, indicating that protein context is critical to polyQ disease 
pathology. Finally, we find that nuclear localization of the expanded polyQ HLD2 protein is 
required for toxicity, in contrast to the purely cytoplasmic localization of toxic polyQ HTT 
proteins in the Drosophila models.  
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Results 
Generating Drosophila models of HDL2  
 CAG transcripts from the antisense strand of JPH3 have been found in both BAC HDL2 
model mice and post-mortem human brain tissue (4, 10). 5’ RACE experiments in the BAC 
HDL2 mouse model indicate two active start sites (10). The full-length isoform was selected for 
our experiments (Seixas et al., 2012; Wilburn et al., 2011). The protein encoded by this 
transcript is 82 amino acids, plus the length of the polyQ region. A schematic of the JPH3 locus, 
antisense open reading frame, and sequence in shown in Figure 1A and B. No HGNC-approved 
gene symbols have been determined for the antisense CAG product. We refer to the antisense 
gene at the JPH3 locus that contributes to toxicity in HDL2 as HDL2, and the polyQ protein 
product as HDL2. De novo synthesis of the antisense transcripts with either 15 or 138 CAG 
repeats was performed. These constructs are referred to as HDL2-Q15 and HDL2-Q138. HDL2-
Q15 is 291 base pairs (97 amino acids, 11 kDa), and HDL2-Q138 is 660 base pairs (220 amino 
acids, 27 kDa). Although repeat lengths larger than 60 have not yet been observed in HDL2, we 
choose a larger Q138 repeat length to be able to compare phenotypes to a previously generated 
HD Q138 model we have generated. 
 Before generating Drosophila models, we tested these constructs in insect S2 cell 
cultures. Transfection in S2 cells revealed that the expanded GFP-HDL2-Q138 proteins form 
large aggregates, while GFP-HDL2-Q15 remains diffuse or forms smaller aggregates 
(Supplementary Material, Figs. S1A, S1B). HDL2 protein distribution in S2 cells is similar to 
that of expanded mRFP-HTT-Q138 (aggregated) or non-pathogenic RFP-HTT-Q15 (diffuse) 
(Supplementary Material, Fig. S1C). HDL2-Q15 and –Q138 constructs were subsequently 
cloned into Drosophila expression vectors for integration into the embryonic germline. Three 
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variants were made for each gene: untagged, N-terminal GFP tag and N-terminal mRFP tag (Fig. 
1C). The constructs were inserted at random sites in the Drosophila genome to allow for 
transgenic lines expressing varying levels of the HDL2 protein. The resulting flies carry an 
upstream activating sequence (UAS) in front of HDL2-Q15 or –Q138, allowing for temporal and 
spatial control via the UAS-GAL4 system. Given that HDL2 and HD patients share similar 
neuropathologies, we investigated whether mechanisms of toxicity might be similar between the 
two proteins in Drosophila models. We selected HD model flies that we previously generated 
using a caspase-6 cleavage fragment of the human HTT gene downstream of a UAS sequence. 
The resulting protein is comprised of the first 588 amino acids of HTT, contains 138 CAG 
repeats, and can be visualized by its N-terminal mRFP tag (13). To ensure the effects of HDL2-
Q138 expression are the result of the unique protein context and not simply due to the polyQ 
tract, we also compared HDL2 transgenic flies to those expressing a pure polyQ protein, Q127 
(14). The Q127 transgene is downstream of a UAS sequence and tagged with HA. 
 
Neuronal expression of HDL2-Q138 causes dose-dependent lethality 
 To investigate the effects of HDL2 expression in Drosophila, UAS-HDL2 flies were 
crossed to elav-GAL4 flies to generate progeny that expressed HDL2 transgenes strongly 
throughout the nervous system. Pan-neuronal expression of HDL2-Q15 is not toxic in any of the 
lines we generated. There was no difference between animals expressing untagged, GFP-tagged, 
and mRFP-tagged constructs. Conversely, pan-neuronal expression of HDL2-Q138 was highly 
toxic. Due to random genomic integration of the construct, UAS-HDL2 lines have varying 
expression levels as observed by fluorescent intensity of the expressed tagged HDL2 proteins. In 
strong expressing lines, elav>HDL2-Q138 resulted in early pupal lethality, with animals dying 
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shortly after the 3rd instar larval stage. There was no difference in toxicity between flies 
expressing untagged HDL2-Q138 versus constructs with mRFP or GFP tags. An mRFP-tagged, 
high expression line was selected for use in the rest of the experiments. As observed for HDL2-
Q138, pan-neuronal expression of mRFP-HTT-Q138 or Q127-HA is also lethal before 
adulthood.  
 
HDL2-Q15 is soluble, while HDL2-Q138 aggregates localize to different compartments 
across specific cell types 
To determine the subcellular compartment potentially responsible for HDL2 toxicity, we 
analyzed the localization of mRFP-HDL2-Q15 and mRFP-HDL2-Q138 in three cell types: 
multidendritic peripheral neurons (pickpocket-GAL4), muscle cells (mef2-GAL4) and epithelial 
cells of the salivary gland (elav-GAL, a neuronal driver that also expresses in salivary glands). In 
all cell types tested, mRFP-HDL2-Q15 remained diffuse throughout the nucleus and cytoplasm, 
occasionally forming small puncta (Figs. 2A, E, I). In contrast, mRFP-HDL2-Q138 aggregated 
in all cell types tested, with inclusions forming in distinct compartments across different tissues 
(Figs. 2B, F, J). In multidendritic peripheral neurons, mRFP-HDL2-Q138 aggregates in the 
nucleus (Fig. 2B). mRFP-HDL2-Q138 localization in muscles is similar to that observed in 
neurons: nuclear aggregates are always observed, and the protein appears as smaller puncta in 
the cytoplasm (Fig. 2F). In contrast to nuclear aggregates formed in neurons and muscles, strong 
expression of mRFP-HDL2-Q138 in salivary gland epithelial cells leads to cytoplasmic 
aggregates (Fig. 2J). Hence, aggregates are consistently observed in all tissues examined, but the 
distribution of mRFP-HDL2-Q138 varies in different cell types. 
 We next compared the localization of mRFP-HDL2-Q138 to that of mRFP-HTT-Q138. 
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While mRFP-HDL2-Q138 forms nuclear aggregates in neurons and muscles, mRFP-HTT-Q138 
is strictly cytoplasmic in these tissues in the Drosophila HD model. mRFP-HTT-Q138 is not 
observed in the nucleus of neurons, muscles, or epithelial cells (Figs. 2C, G, K). In HD patients 
and mammalian models, N terminal fragments produced by caspase and calpain cleavage events 
have been found to cause nuclear aggregates (15–18). Drosophila do not cleave HTT to liberate 
smaller N terminal pieces from the 588-amino acid fragment expressed in our model, which may 
explain why the protein remains confined to the cytoplasm (13).  
 We next compared mRFP-HDL2-Q138 localization to that of Q127-HA, a pure polyQ 
tract with no surrounding protein. As with mRFP-HDL2-Q138, neuronal expression of Q127-HA 
leads to nuclear aggregates in neurons (Fig. 2D). Similarly, Q127-HA aggregates in the nuclei of 
muscle cells (Fig. 2H). Q127-HA puncta are rarely observed in the muscle cytoplasm. A 
pronounced distinction between mRFP-HDL2-Q138 and Q127-HA localization was observed in 
salivary gland epithelial cells. While mRFP-HDL2-Q138 aggregates in the cytoplasm of this cell 
type, Q127-HA forms nuclear aggregates (Figs. 2J, L). These experiments indicate HDL2 
aggregation is polyQ-length dependent in both neuronal and non-neuronal cell types. 
Furthermore, mRFP-HDL2-Q138 localization is distinct from that of pathogenic mRFP-HTT-
Q138 or a pure polyQ tract. Table 1 summarizes the localization of mRFP-HDL2-Q138, mRFP-
HTT-Q138, and Q127-HA in the cell types analyzed. 
 
HDL2-Q138 expression does not induce axonal trafficking or synaptic defects 
 We next investigated and compared mRFP-HDL2-Q138 and mRFP-HttQ138 expression 
in glutamatergic motor neurons and neuromuscular junction (NMJ) synapses using elav-GAL4. 
As previously observed, mRFP-HTT-Q138 forms large immobile aggregates along axons (Fig. 
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3E) that interfere with axonal transport and result in the accumulation of transport cargo at these 
sites of blockage (13). As observed in peripheral neurons, mRFP-HDL2-Q138 expression results 
in aggregates in the nucleus of ventral nerve cord (VNC) motor neurons (Fig. 3A). mRFP-
HDL2-Q138 often forms a single nuclear inclusion, but low levels of soluble mRFP-HDL2-
Q138 are also observed in nuclei. The HDL2-Q138 protein is also trafficked along axons as 
small aggregates or puncta (Fig. 3D), but does not lead to large axonal aggregates or a blockage 
in axonal transport as observed with pathogenic HTT. In contrast to HDL2 and HTT pathogenic 
proteins, we did not observe Q127-HA in axons, but instead found it in nuclear aggregates (Figs. 
3C, F). We conclude that HDL2 does not manifest large axonal aggregates that disrupt transport 
as observed in our Drosophila HD model (13). 
 We next examined NMJ synaptic terminals where motor neurons contact muscle fibers. 
After contacting the muscle fiber, immature filopodia at the NMJ develop synaptic varicosities, 
termed boutons, which serve as site for communication between nerve and muscle (19). The 
relationship between the neuron and muscle is plastic and changes in response to neural activity 
and muscle growth. Failure to coordinate activity-dependent synaptic growth can lead to under- 
or over-developed NMJs. Both soluble and aggregated mRFP-HTT-Q138 readily localize to the 
synapse, and expression of mRFP-HTT-Q138 induces synaptic overgrowth with supernumerary 
satellite boutons due to a disruption in the trafficking of synaptic growth factor receptors (Fig. 
3H, Akbergenova and Littleton, unpublished data). Small mRFP-HDL2-Q138 puncta are 
occasionally found at synaptic boutons, but the toxic protein does not form large aggregates like 
those observed in nuclei, and does not induce synaptic overgrowth (Fig. 3G, arrowheads). As 
such, the peripheral pathologies associated with pathogenic HTT on axonal transport and 
synaptic development are absent in the HDL2 model. To look for more subtle defects in synaptic 
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properties, we performed electrophysiology at the NMJ to determine if mHDL2-Q138 perturbed 
synaptic transmission. Neuronal expression of mRFP-HDL2-Q138 did not significantly impair 
spontaneous or evoked release (Supplementary Material, Fig. S2), suggesting synaptic 
transmission is not disrupted at this stage of development by pathogenic HDL2. In contrast to 
HDL2 and Htt, the polyQ protein Q127-HA alone is not observed in axons or at the NMJ (Fig. 
3F, I). Expression of Q127-HA also does not induce synaptic overgrowth (Fig. 3I), suggesting 
this effect is specific for the pathogenic HTT protein, which displays prominent synaptic 
aggregates.  
 
mRFP-HDL2-Q138 does not localize to the nucleolus or impair nuclear import  
 Given the lack of axonal transport or synaptic transmission defects in HDL2 expressing 
animals, we examined other cellular compartments where toxicity could arise. Unlike mRFP-
HTT-Q138, which remains in the cytoplasm, mRFP-HDL2-Q138 aggregates in neuronal nuclei. 
Within the nucleus, mRFP-HDL2-Q138 usually forms a single, dense aggregate. We 
hypothesized that mRFP-HDL2-Q138 may be aggregating within the nucleolus, which would 
suggest certain pathologies. The nucleolus is a non-membrane-bound subdomain within the 
nucleus where ribosomal subunits are assembled. In addition to its primary role in ribosome 
biogenesis, the nucleolus also plays roles in cellular stress responses, DNA damage and repair, 
and other processes (20). Nucleoli can be visualized by staining for fibrillarin, a component of 
rRNA processing machinery (21). As in wild-type animals, staining with anti-fibrillarin in 
elav>mRFP-HDL2-Q138 larvae revealed a single nucleolus in each nucleus. mRFP-HDL2-Q138 
aggregates did not co-localize with the nucleolus, nor did aggregates consistently appear adjacent 
to the nucleolus. These data indicate HDL2-Q138 aggregates and the nucleolus reside in separate 
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domains within the nucleus (Supplementary Material, Fig. S3).  
 We next investigated whether mRFP-HDL2-Q138 interrupts nuclear transport, a process 
recently shown to be defective in frontotemporal dementia and amyotrophic lateral sclerosis 1 
(FTDALS1) models (22–24). Neuronal cell bodies are tightly packed in the brain, making it 
challenging to target just one nucleus for analysis. Therefore, we expressed mRFP-HDL2-Q138 
or mRFP-HDL2-Q15 in muscle cells and analyzed nuclear import with fluorescence recovery 
after photobleaching (FRAP) experiments. Drosophila larval muscle fibers are large, multi-
nucleate cells that are very accessible to FRAP. Using the mef2-GAL4 muscle driver, we co-
expressed mRFP-HDL2-Q15 or mRFP-HDL2–Q138 and a genetically encoded fluorescent 
protein fused to a nuclear localization signal (NLS), GPF-NLS. GFP-NLS is concentrated in the 
nuclei of muscle cells. If pathogenic HDL2 interfered with nuclear import, we hypothesized that 
nuclear GFP would recover more slowly in larvae expressing mRFP-HDL2-Q138 as compared 
to mRFP-HDL2-Q15. However, FRAP experiments did not reveal any difference in fluorescence 
recovery time between these genotypes (Supplementary Material, Fig. S4). These results suggest 
that disruption of nuclear import is not likely to be a primary pathogenic mechanism in this 
HDL2 model. 
 
Addition of a nuclear import or nuclear export tag alters localization of HDL2  
 Given that soluble and aggregated mRFP-HDL2-Q138 localize to the nuclei of neurons, 
we examined if localization played a role in toxicity. Nuclear localization has been shown to be 
critical for disease pathogenesis in HD, spinocerebellar ataxia 1 (SCA1) and other polyQ 
disorders. One strategy would be to modify intrinsic NLS or nuclear export sequences (NES), but 
we could not identify any canonical NLS or NES within the HDL2 protein using bioinformatics 
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approaches. To redirect HDL2, we created transgenic Drosophila expressing HDL2 where we 
added a NLS or NES tag to the C terminus of HDL2-Q15 and HDL2-Q138, along with a GFP 
tag at the N terminus. Constructs expressing GFP-HDL2-Q15 and GFP-HDL2-Q138 with an 
NLS, NES, or no tag were inserted into the same attP2 genetic docking site using the phiC31 
targeted integration system, which ensures equal expression among all transgenic lines using the 
UAS system (Figs. 4A, D, G). Semi-quantitative RT-PCR of HLD2 confirmed that the lines 
express similar mRNA levels (Supplementary Material, Fig. S5). Lines obtained from these site-
directed injections do not express transgenes as strongly as some of the lines obtained by 
integration at random sites. Hence, dose-dependent metrics like lethality differed from the 
mRFP-HDL2-Q138 high expression lines used in the previously described experiments. These 
site-directed lines will be denoted with superscript “attP2” to differentiate them from the random 
insertion lines described above.  
 First, we assayed if NLS and NES tags successfully redirected the HLD2 protein. We 
examined several tissue types, including the large, multinucleate larval muscle cells. Using the 
muscle driver mef2-GAL4, expression of GFP-HDL2-Q138attP2 results in large nuclear 
aggregates, along with small aggregates in the cytoplasm (Fig. 4B). Expression of GFP-HDL2-
Q138-NLSattP2 also leads to nuclear aggregate formation, but lacks any detectable cytoplasmic 
HDL2-Q138 protein (Fig. 4E). In contrast, no nuclear fluorescence is observed in animals 
expressing GFP-HDL2-Q138-NESattP2, and the protein is visible as only cytoplasmic aggregates 
(Fig. 4H). These experiments demonstrate that the NLS and NES tags redirect the HDL2 protein 
as intended. 
 
Nuclear localization and polyQ tract expansion are required for HDL2 toxicity in muscles 
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 After determining that the NLS and NES tags target the protein to the desired 
compartments, we investigated the effects of nuclear or cytoplasmic localization on toxicity. 
Using the mef2-GAL4 muscle driver, expression of GFP-HDL2-Q138attP2 is lethal at the 3rd instar 
larval stage (Fig. 4C). Dead larvae appear dark colored, suggesting necrotic cell death is 
occurring. Toxicity is exacerbated with nuclear localization. Animals expressing GFP-HDL2-
Q138-NLSattP2 die earlier in development, during the 2nd instar, and also turn a dark color (Fig. 
4F). Strikingly, nuclear export completely rescues lethality, as animals with muscle expression of 
GFP-HDL2-Q138-NESattP2 are viable (Fig. 4I). Adult flies appear healthy, with no phenotypic 
abnormalities such as wing inflation defects or motor incoordination detected. We also expressed 
non-pathogenic GFP-HDL2-Q15attP2 in muscle. Muscle expression of all Q15 variants (GFP-
HDL2-Q15attP2, GFP-HDL2-Q15-NLSattP2, and GFP-HDL2-Q15-NESattP2) were adult viable. 
Hence, nuclear localization alone is not sufficient for toxicity. Instead, HDL2 toxicity requires 
both nuclear localization and the expanded polyQ tract. 
 
Nuclear localization of HDL2-Q138 is required for neuronal toxicity  
 We next expressed GFP-HDL2-Q138attP2, GFP-HDL2-Q138-NLSattP2 and GFP-HDL2-
Q138-NESattP2 in the Drosophila eye using the GMR-GAL4 driver. The eye is comprised of 
hundreds of ommitidia, each containing eight photoreceptor neurons (Fig. 5A). This highly 
organized structure provides a conducive system to study neurodegenerative processes (25). 
Expression of GFP-HDL2-Q138attP2 does not result in any obvious defects in eye anatomy (Fig. 
5B). GFP-HDL2-Q138-NESattP2 expression is also indistinguishable from controls (Fig. 5D). 
However, directing the HDL2 polyQ protein to the nucleus (GFP-HDL2-Q138-NLSattP2) causes a 
severe rough eye degenerative phenotype, indicating that nuclear localization of expanded HDL2 
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enhances toxicity (Fig. 5C). 
 To examine how nuclear localization or export affects toxicity of the HDL2 protein in the 
CNS, we used elav-GAL4 to express GFP-HDL2-Q138attP2, GFP-HDL2-Q138-NLSattP2 or GFP-
HDL2-Q138-NESattP2 throughout the nervous system. Neuronal expression of all three lines is 
adult viable due to the lower expression of genes from the attP2 site. However, within days of 
eclosion, motor defects begin to appear. To measure motor deficits we employed a climbing 
assay, which quantified the percentage of flies that were able to climb two centimeters or more in 
a 30-second time period (Fig. 6A, Movie S1). Healthy flies exhibit negative geotaxis, 
immediately climbing upward when shaken to the bottom of a vial. One day after eclosion, flies 
expressing GFP-HDL2-Q138-NLSattP2 exhibit normal climbing behavior. However, one week 
after eclosion, flies with HDL2-NLS exhibit severely impaired motor function. Flies expressing 
the unmodified or NES constructs had no impairments at one week of age. By three weeks of 
age, GFP-HDL2-Q138attP2 flies failed to climb, while GFP-HDL2-Q138-NES attP2 flies performed 
as well as controls. By week five, the climbing ability of HDL2-Q138-NESattP2 flies remained 
indistinguishable from controls. Hence, nuclear localization of GFP-HDL2-Q138 accelerates the 
onset of motor dysfunction, while nuclear export completely suppresses motor defects caused by 
GFP-HDL2-Q138 expression in the climbing assay. 
 Nuclear localization or nuclear export of HDL2-Q138 has an equally robust effect on 
lifespan (Fig. 6B). At 29°C, the median survival of control flies is 43 days. When GFP-HDL2-
Q138attP2 is expressed in neurons with the elav-GAL4 driver, median survival drops to 28 days. 
Nuclear localization further reduces lifespan, with GFP-HDL2-Q138-NLSattP2 flies displaying a 
median survival of 10 days. In contrast, nuclear export of HDL2 completely rescues the lifespan 
reduction. The median survival for flies expressing GFP-HDL2-Q138-NESattP2 is 45 days, 
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similar to controls. In conclusion, nuclear localization of HDL2-Q138 enhances toxicity in 
multiple tissue types (muscles, eyes, and neurons), while removal of HDL2-Q138 from the 
nucleus completely suppresses toxicity.  
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Discussion  
We have generated and characterized a Drosophila HDL2 model to examine how an 
HDL2 polyQ protein may exert toxicity. In addition, we compared pathology to that we 
previously identified in one Drosophila HD model or strains that express a pure polyQ tract. Our 
findings indicate that nuclear localization of HLD2-Q138 is required for toxicity and that the 
HDL2 and HTT polyQ proteins cause toxicity in different cellular compartments in Drosophila.  
 In the current study, we found that expanded HDL2-Q15 is not toxic to Drosophila. 
HDL2-Q15 protein remains diffuse throughout the nucleus and the cytoplasm in cultured S2 
cells, neurons, epithelial cells and muscles (Figs. 2A, E, I). Concentrating it in the nucleus with 
an NLS tag does not cause toxicity, suggesting the HDL2 unexpanded protein is nonpathogenic. 
While unmodified (HDL2-Q138attP2) and nuclear-targeted (HDL2-Q138-NLSattP2) versions of 
expanded HDL2 are pathogenic in muscle tissue, all HDL2-Q15attP2 constructs are viable to 
adulthood. Similarly, no defects are observed with neuronal expression of unmodified or NLS 
tagged HDL2-Q15attP2. Hence, the combination of nuclear localization and pathogenic polyQ 
expansion is required for pathology in Drosophila. In contrast to HDL2-Q15, expression of 
HDL2-Q138 is highly toxic. Neuronal expression from the strongest HDL2 lines (generated 
through random P-element insertion) causes early pupal lethality, while low-expressing lines 
(generated from attP2 site-direction insertion) are adult viable with progressive onset of motor 
defects and eventual lethality. This dose-dependent lethality agrees what has been observed in 
Drosophila HD models (13).  
This study required the use of long polyQ repeat lengths within HDL2, as this accelerates 
toxicity and is needed for animals with short lifespans like Drosophila. The generation of animal 
models with CAG stretches longer than the median repeat length of the patient population is a 
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common approach in the polyQ field. For example, studies sampling thousands of HD patients 
have found the median HTT CAG repeat length is 43-46 (26–31). In contrast, most HD mouse 
models are generated using CAG lengths near or over 100 repeats, including the popular R6/2 
model, which has a repeat length of around 150 (32–52). Similar ranges are found in Drosophila 
models of HD, where pathogenic HTT constructs contain up to 152 repeats (13, 53–60). These 
animal models have accelerated onset of phenotypes, and may induce distinct pathologies than 
those observed in human neurons that have expressed the toxic protein for decades.  
 In Drosophila neurons, the cellular localization of HDL2-Q138 suggests mechanisms of 
toxicity are likely distinct from what we observed previously in an HD model we created. The 
Drosophila HD model used in these experiments contains a 588-amino acid fragment spanning 
exons 1 to 12 of the human Htt locus, which corresponds to a known cleavage product of full-
length HTT. In neurons, HDL2-Q138 aggregates in the nucleus, often forming one large 
inclusion (Figs. 2B, 3A). This observation is similar to findings from HD and HDL2 patient 
brain tissue, where aggregated protein often forms one large nuclear inclusion, although multiple 
inclusions per nucleus are occasionally found (2, 61). The nuclear aggregation of HDL2-Q138 
contrasts with several Drosophila models of HD, where pathogenic HTT remains confined to the 
cytoplasm (Figs. 2C, G, K, 3B) (13, 54, 56). Furthermore, while HTT-Q138 forms large axonal 
aggregates, HDL2-Q138 is trafficked down the axon as small puncta (Figs. 3D, E). Despite these 
differences in neurons, HDL2-Q138 and HTT-Q138 share a similar distribution pattern in 
epithelial cells of the salivary gland, where both form cytoplasmic aggregates (Figs. 2J, K). It 
will be interesting to determine if salivary glands lack important nuclear factors for HDL2 that 
normally trigger nuclear aggregation, or alternatively express cytoplasmic proteins that promote 
aggregation within this compartment before nuclear accumulation can occur. While these 
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findings represent data from one Drosophila HD model, it will be important to test additional 
disease-relevant HTT species in the future, including those where the protein is forced into the 
nucleus with an NLS tag. Furthermore, it is important to note that mutant HTT is not cleaved and 
processed in Drosophila the same way it is in mammalian neurons (13). It would therefore be 
worthwhile to study the similarities and differences between HDL2 and full-length HTT in 
mammalian models as well. Ultimately, modeling the polyQ diseases in a variety of systems will 
allow for deeper inquiry into mechanisms of toxicity.  
In addition to differences from HTT-Q138, HDL2-Q138 localization is also distinct from 
a pure polyQ tract protein. While Q127 and HDL2-Q138 form nuclear aggregates in neurons, 
Q127 is not transported along axons (Figs. 2B, D, 3A, C, D, F). In muscle, both form nuclear 
aggregates, but HDL2-Q138 is also observed as puncta in the cytoplasm while Q127 is rarely 
observed outside of the nucleus (Figs. 2F, H). In epithelial cells of the salivary gland, HDL2-
Q138 aggregates in the cytoplasm, while Q127 aggregates in the nucleus (Figs. 2J, L). As such, 
HDL2-Q138 appears distinct from either pathogenic HTT or an expanded polyQ tract in its 
aggregation pattern across a population of cell types in Drosophila (Table 1).  
 Distinctions between HDL2-Q138 and HTT-Q138 are also apparent at synapses of 
glutamatergic motor neurons. In our Drosophila HD model, HTT-Q138 accumulates locally at 
the NMJ and induces a synaptic overgrowth phenotype characterized by supernumerary satellite 
boutons (Fig. 3H). In contrast, HDL2-Q138 can be found as small puncta at the NMJ, but does 
not accumulate in appreciable quantities or form large aggregates (Fig. 3G). Neuronal expression 
of HDL2-Q138 does not lead to impaired synaptic function that we can measure through 
physiological analysis (Supplementary Material, Fig. S2). It is possible that physiological deficits 
are occurring in the central nervous system, or would appear at more mature synapses. Since 
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these experiments were conducted using a neuronal driver, only the presynaptic partner (the 
neuron) expressed HDL2-Q138, while the postsynaptic partner (the muscle) did not. Given 
HDL2-Q138 is expressed both pre- and post-synaptically, it will be interesting to examine 
postsynaptic effects of HDL2 expression in future studies.  
 Experiments redirecting HDL2 into or out of the nucleus demonstrate that nuclear 
mechanisms are critical to HDL2-Q138-induced toxicity. NES or NLS tagging redistributes the 
HDL2-Q138 protein to the desired compartment (Figs. 4B, E, H). This is important to note in 
light of research in HD models, where addition of NES tags reduce nuclear contribution of HTT, 
but some nuclear aggregates are still present (62, 63). The SV40 NLS sequence and modified 
PKI NES sequence used in our experiments alter the localization of all detectable HDL2 protein. 
The effect of nuclear localization or nuclear export of HDL2-Q138 is consistent across various 
tissues. Expression of an unmodified HDL2-Q138attP2 is not sufficient to cause eye degeneration, 
but targeting the protein to the nucleus induces a rough eye degenerative phenotype (Fig. 5). In 
muscle tissue, nuclear localization of HDL2-Q138 accelerates lethality, while nuclear export 
completely suppresses toxicity induced by the protein (Figs. 4C, F, I). In neurons, nuclear 
localization accelerates onset of motor dysfunction and significantly reduces lifespan compared 
to animals expressing the untagged HDL2-Q138attP2 (Fig. 6). Strikingly, motor function and 
lifespan are fully restored to control levels when the protein is confined to the cytoplasm. This 
complete suppression demonstrates that nuclear localization of an expanded HDL2 polyQ 
protein is required for the manifestation of pathology in the Drosophila model.  
 The importance of nuclear localization to HDL2 toxicity is interesting given that nuclear 
localization exacerbates toxicity in HD, but cytoplasmic mechanisms also play a role in 
pathogenesis. Addition of an NLS to HTT-Q144 accelerates onset of disease phenotypes in 
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transgenic mice. However, disease pathogenesis is not exclusively due to nuclear (e.g., 
transcriptional) aberrations, as affected neurons have dark and degenerating organelles and 
swollen axons, indicating cytoplasmic dysfunction as well. Furthermore, addition of an NES tag 
to HTT-Q144 does not fully suppress mutant phenotypes (63). Similar results were obtained in in 
vitro experiments. Addition of an NLS tag to a fragment of HTT-Q75 doubled the percent of 
cells lost, while NES-tagged HTT-Q75 reduced cell loss, but did not fully suppress toxicity (62). 
Finally, multiple Drosophila models of HD display pathogenesis without nuclear localization of 
the pathogenic HTT protein, further demonstrating that cytoplasmic mechanisms are sufficient to 
induce toxicity in these HD models (13, 54, 56). These data demonstrate that although nuclear 
localization of mutant HTT is detrimental, both nuclear and cytoplasmic events contribute to 
pathogenesis. This contrasts with our findings for pathogenic HDL2, which induces toxicity only 
when the protein accumulates in the nucleus. 
 The toxic contribution of nuclear versus cytoplasmic protein load has also been studied in 
other polyQ disease models. Similar to what has been observed in HD, nuclear localization 
exacerbates phenotypes in MJD model mice. However, nuclear export does not completely 
suppress toxicity (64). In contrast, nuclear localization is essential for toxicity in SCA1. In 
transgenic mouse models of SCA1, expanded ataxin-1 localizes to the nucleus, and animals 
exhibit motor defects followed by atrophy or loss of Purkinje cells (65, 66). When expanded 
ataxin-1 is blocked from nuclear entry, toxicity is fully suppressed, with no apparent behavioral 
defects or neuropathology (67). Nuclear mechanisms are also important to disease pathogenesis 
in dentatorubro-pallidoluysian atrophy (DRPLA). DRPLA patients and transgenic mouse models 
present with nuclear accumulation of atrophin-1. Cell culture experiments show that directing 
expanded atrophin-1 to the nucleus increases toxicity, while mutating the NLS restores cell loss 
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to control levels (68). Nuclear localization is not required for toxicity in all polyQ diseases. In 
the case of spinocerebellar ataxia 2 (SCA2), pathology occurs without nuclear ataxin-2 protein. 
In contrast to patients with HDL2, HD, SCA1, or MJD, postmortem brain tissue from patients 
with SCA2 does not reveal polyQ neuronal nuclear inclusion, nor is expanded ataxin-2 observed 
in the nucleus in a SCA2 mouse model (69). Current hypotheses suggest SCA2 pathogenesis 
may arise from impaired calcium signaling or dysfunctional RNA regulation and transport, but 
the mechanisms of cellular toxicity remain unclear (70–73). 
While HDL2 patients’ symptoms and neuropathology mimic HD, dysfunction at the 
molecular level may be reminiscent of another polyQ disorder, SCA1, where nuclear localization 
of the pathogenic protein is required for toxicity. The mechanism of nuclear toxicity in HDL2 
remains an open question. Staining with anti-fibrillarin demonstrates that the expanded HDL2-
Q138 protein does not localize to the nucleolus (Supplementary Material, Fig. S3). This 
observation matches findings from brain tissue of patients with HD, DRPLA, SCA1, and MJD, 
where the polyQ proteins tend to form single large inclusions that remain distinct from the 
nucleolus (61, 74–76). Also, FRAP experiments suggest that HDL2-Q138 does not appear to 
alter nuclear transport (Supplementary Material, Fig. S4), a pathogenic mechanism that is 
emerging in models of FTDALS1 (22–24). 
There are a variety of mechanisms by which nuclear localization of pathogenic HDL2 
may exert toxicity. One potential mechanism is transcriptional dysregulation, a well-established 
pathogenic pathway in the polyQ disorders (suggested reviews: J. H. J. Cha, 2007; J. H. Cha, 
2000; Riley & Orr, 2006; Sugars & Rubinsztein, 2003). A comprehensive transcriptional 
profiling of HDL2 mutant animals via RNA sequencing could provide a starting point to delve 
deeper into mechanisms of polyQ toxicity in HDL2. Similarly, epigenetic changes may play a 
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role in HDL2 pathogenesis. This pathway that has been studied in depth in polyQ diseases, 
trinucleotide repeat expansion disorders, and other neurodegenerative diseases, such as 
Alzheimer’s and Parkinson’s (81–86). It also represents an attractive therapeutic approach given 
several pharmacological agents are available to modify epigenetic state (such as histone 
deacetylase inhibitors). Since DNA damage has been established as playing a role in a variety of 
neurodegenerative diseases, HDL2 nuclear localization could also disrupt this process (87–90). 
HDL2 nuclear aggregates or monomers could sequester or otherwise interfere with other nuclear 
proteins. For example, experiments in a SCA1 models show that expanded ataxin-1 causes a 
redistribution of the nuclear matrix-associated domain containing promyelocytic leukaemia 
protein (75).  
The cause of human pathology in HDL2 remains an open question. Several pathogenic 
pathways have experimental support in the field, including JPH3 loss of function, CUG RNA 
toxicity, and polyQ toxicity (91). Evidence from both HDL2 mouse models and HDL2 patient 
brain tissue suggest a polyQ protein may be involved in disease pathology. First, an antisense 
CAG transcript has been identified in human brain tissue (normal repeat length transcript) and an 
HDL2 mouse model (expanded length transcript) (4, 10). While the full-length transcript has not 
been isolated from human patient brain tissue, the possibility remains that the transcript is 
produced in neuronal populations other than frontal cortex, the only brain area tested (4). The 
nature of neurodegenerative diseases makes this a particularly difficult technical method, since 
the main neuronal populations of interest have been lost to disease. Additional evidence 
supporting a polyQ pathology comes from the observation that ubiquitinated neuronal inclusions 
have been found in human HDL2 patient brain tissue, as well as brain tissue from the HDL2 
mouse models (2, 10). Immunohistochemistry on human patient and mouse model brain sections 
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have confirmed the inclusions can be stained with 1C2, an antibody that recognizes polyQ 
proteins. Inclusions in the mouse model were also tested with the 3B5H10 antibody, a more 
specific polyQ antibody (10). Hence, the multimodal pathogenesis of HDL2 may involve 
contribution from a toxic polyQ protein (91, 92), although other mechanisms likely contribute to 
the disease mechanism as well. 
 In conclusion, these experiments demonstrate that nuclear localization of the HDL2 
polyQ protein is required for pathogenesis in a Drosophila model of the disorder. This contrasts 
with a Drosophila HD model expressing an N-terminal fragment of HTT, where toxicity occurs 
through cytoplasmic mechanisms. Confining HDL2-Q138 to the cytoplasm completely 
suppresses toxicity in a variety of tissue types tested, including neurons. In addition, nuclear 
export restores motor function and lifespan to control levels. In contrast, adding a NLS to HDL2-
Q138 enhances pathology and decreases lifespan compared to unmodified HDL2-Q138. Thus, 
although similar neurological profiles are found in HD and HDL2 patients, HDL2 pathology may 
principally occur due to its accumulation within the nucleus. This contrasts with HD, where both 
nuclear and cytoplasmic pathology has been well documented. Additional research comparing 
our HDL2 Drosophila model with other Drosophila models of HD, along with comparing these 
polyQ proteins in mammalian models, may provide insight into mechanisms of toxicity and 
reveal additional similarities and differences between HD and HDL2.  
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Materials and methods 
JPH3 antisense (HDL2) gene synthesis 
 Sequences were selected based on transcripts identified by 5’ RACE experiments in 
BAC-HDL2 model mice (4, 10). The full-length isoform was used in these experiments. No 
HGNC-approved gene symbols have been determined for the antisense CAG product. The 
antisense gene at the JPH3 locus that contributes to toxicity in HDL2 is referred to as HDL2, and 
the polyQ protein product as HDL2. HDL2 constructs with either 15 or 138 CAG repeats 
(HDL2-Q15, HDL2-Q138) were synthesized and cloned into the pENTR1A Gateway® entry 
vector by Epoch Life Science. 
 
Drosophila stocks and transgenics 
 All Drosophila strains were cultured on standard media at 25°C. GAL4 driver lines (elav, 
mef2, pickpocket) and GFP control lines (UAS-GFP, UAS-GFP-NLS) were obtained from the 
Bloomington Drosophila Stock Center. Generation of HD model flies was described previously 
(13). To generate flies carrying HDL2 transgenes at random insertion sites, HDL2-Q15 and -
Q138 in pENTR1A were cloned into pUASt vectors pTRW, pTGW, and pTW (Drosophila 
Genomics Resource Center) using the Gateway® cloning system. Constructs were injected into 
Drosophila embryos (genotype w1118) by BestGene. High expression lines selected for analysis 
were mapped to the third chromosome (BestGene). For nuclear localization and nuclear export 
experiments, HDL2 constructs were modified at the 3’ end with the addition of NLS 
(CCTAAGAAGAAGAGGAAGGTT) or NES 
(AACATTAACGAACTGGCGCTGAAATTTGCGGGCCTGGATATT) sequences. Using the 
Gateway® system, constructs were cloned into the pPGW (Drosophila Genomics Resource 
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Center) vector and injected into Drosophila embryos (genotype y1 w67c23; P{CaryP}attP2) by 
BestGene.  
  
Immunohistochemistry 
 Wandering 3rd instar larvae reared at 25°C and dissected in HL3.1 solution, containing (in 
mM): 70 NaCl, 5 KCl, 4 MgCl2, 10 NaHCO3, 5 Trehalose, 115 sucrose, 5 HEPES-NaOH, pH 
7.2, and 0.2 Ca++. Larvae were fixed for 30 minutes in 4% formaldehyde, permeabilized for 30 
minutes in 0.1% Triton-X100 in PBS (PBX), and blocked for 1 hour in 2% normal goat serum in 
PBX. The following antibodies were used: rat anti-elav (DSHB), mouse anti-lamin C (DSHB), 
FITC conjugated rabbit anti-HA (Abcam), Alexa Fluor® 647 goat anti-HRP (Jackson 
ImmunoResearch), Alexa Fluor® 405 goat anti-rat (Abcam), Alexa Fluor® 405 goat anti-mouse 
(Life Technologies). Larvae were mounted in Vectashield® antifade mounting medium or 
Vectashield® antifade mounting medium with DAPI (Vector Laboratories). Images were 
captured with a Zeiss Pascal laser scanning confocal microscope (Carl Zeiss MicroImaging, Inc.) 
using the accompanying Zeiss PASCAL software or a spinning disk confocal microscope (Carl 
Zeiss MicroImaging, Inc.) using Perkin Elmer Volocity software. 
 
Eye imaging 
 Drosophila eyes were photographed using a Zeiss Stemi 2000-C stereo microscope (Carl 
Zeiss MicroImaging, Inc.) fitted with a SPOT idea CMOS camera (SPOT Imaging) and captured 
with the accompanying SPOT Imaging software.  
 
Lifespan assay 
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 Drosophila viability assays were performed on male flies aged at 29°C, with 10 flies per 
vial, and transferred every 2-3 days. 50 flies per genotype were used.   
 
Climbing assay 
 Male Drosophila were aged at 29°C, with no more than 10 flies per vial, and transferred 
every 2-3 days. At age 1 day, 1 week, 3 weeks, and 5 weeks, flies were transferred to empty vials 
and left to recover for one hour at room temperature. Flies were then briefly vortexed to knock 
them all to the bottom of the vial and their subsequent climbing was recorded. The percent of 
flies climbing above 2 cm in 30 seconds was used for analysis. 50 flies per genotype were used.   
 
Statistical analysis 
 Analysis of variance (ANOVA) with Tukey’s post-hoc test (Fig. 6A), and the Mantel-
Cox test (Fig. 6B) were used to determine statistical significance using Prism software 
(GraphPad). 
 
OMIM reference numbers 
 Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/omim) reference 
numbers for the disorders described in this paper are as follows: dentatorubro-pallidoluysian 
atrophy (#125370), frontotemporal dementia and/or amyotrophic lateral sclerosis 1 (#105550), 
Huntington disease (#143100), Huntington disease-like 2 (#606438), Machado-Joseph disease 
(#109150), myotonic dystrophy 1 (#160900), spinocerebellar ataxia 1 (#164400), spinocerebellar 
ataxia 2 (#183090), spinocerebellar ataxia 8 (#608768).  
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Legends to Figures 
Figure 1. Generation of a Drosophila HDL2 model.  
(A) Schematic illustrating the JPH3 gene and antisense product. The CTG repeat on the sense 
strand corresponds to a CAG repeat on the antisense strand. This CTG/CAG repeat is expanded 
in HDL2 patients. We chose to express the full-length isoform of the antisense gene product, 
which was identified by 5’ RACE products in a BAC-HDL2 mouse model (4, 10). The construct 
was modified to include a CAG repeat length of 15 (named HDL2-Q15) or 138 (HDL2-Q138). 
(B) DNA and protein sequence of the HDL2-Q15 construct. HDL2-Q138 is identical except for 
the CAG repeat region length. Start sites identified by 5’ RACE are indicated in green, the polyQ 
region is purple, and the stop codon is red. (C) Schematics of HDL2 variants used in these 
experiments. HDL2-Q15 and –Q138 sequences were cloned in vectors with no tag or 5’ 
fluorescent tags. For tagged constructs, resulting proteins have N-terminal RFP (illustrated in 
red) or GFP (illustrated in green) tags. The polyQ region is shown in purple.  
 
Figure 2. Localization of HDL2-Q15, HDL2-Q138, HTT-Q138 and Q127-HA across cell types. 
 (A) In pickpocket>RFP-HDL2-Q15 larval multi-dendritic peripheral neurons, HDL2-Q15 is 
diffuse throughout the cytoplasm and nucleus. (B) pickpocket>RFP-HDL2-Q138 leads to the 
formation of nuclear aggregates. (C) Aggregates in pickpocket>RFP-HTT-Q138 larvae are 
exclusively localized to the cytoplasm, often found peri-nuclear. (D) pickpocket>Q127-HA 
causes nuclear aggregation of the polyQ tract; no Q127 is visible in the cytoplasm. (E) Using the 
mef2-GAL4 muscle driver, RFP-HDL2-Q15 remains diffuse throughout the cytoplasm and 
nucleus in mef2>RFP-HDL2-Q15 larvae. (F) mef2>RFP-HDL2-Q138 larvae have large 
aggregates in the nuclei, along with smaller aggregates or puncta in the cytoplasm. (G) 
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Aggregates remain strictly cytoplasmic in mef2>RFP-HTT-Q138 larvae. (H) Q127-HA 
aggregates in the nucleus of mef2>Q127-HA larvae. Small puncta are rarely observed in the 
cytoplasm. (I) In elav>RFP-HDL2-Q15 epithelial cells of the salivary gland, the polyQ protein 
remains diffuse throughout the cytoplasm and nuclei. (J) elav>RFP-HDL2-Q138 larvae have 
large perinuclear aggregates in the cytoplasm of salivary gland cells, along with lower levels of 
the soluble protein in the nucleus. (K) RFP-HTT-Q138 aggregates are cytoplasmic in salivary 
glands of elav>RFP-HTT-Q138 larvae. (L) Q127-HA aggregates in the nuclei of salivary gland 
cells in elav>Q127-HA larvae. PolyQ proteins are shown in red (RFP-HDL2-Q15, RFP-HDL2-
Q138, RFP-HTT-Q138, or Q127-HA), nuclei stained dark blue (anti-elav, panels A-D; DAPI, 
panels E-L), and anti-HRP to label neuronal membranes is shown in cyan. Images A-D are z-
stacks, while images E-L are single confocal planes.  
 
Figure 3. HTT-Q138 forms large axonal aggregates and disrupts synapse formation at the NMJ, 
while HDL2-Q138 does not. 
 (A) RFP-HDL2-Q138 localizes to the nuclei of motor neurons in elav>RFP-HDL2-Q138 larvae. 
HDL2-Q138 is often observed as a single large nuclear inclusion with low levels of soluble 
protein in the same nucleus. (B) In elav>RFP-HTT-Q138 larvae, aggregates are never observed 
inside nuclei. (C) In elav>Q127-HA larvae, Q127 forms nuclear inclusions. (D) In elav>RFP-
HDL2-Q138 animals, the polyQ protein is observed along axons as puncta or small aggregates. 
(E) elav>RFP-HTT-Q138 larvae have large axonal aggregates. (F) In contrast, elav>Q127 
animals have no detectable Q127 along axons. (G) In elav>RFP-HDL2-Q138 larvae, RFP-
HDL2-Q138 is visible in the axon near the NMJ (circled). The protein does not usually localize 
to synaptic terminals at the NMJ, however, it is occasionally found within a bouton (arrowhead). 
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(H) elav>RFP-HTT-Q138 larvae have soluble and aggregated RFP-HTT-Q138 at the synapse, 
and expression of mutant HTT induces formation of excess synaptic boutons (arrowheads). (I) 
No polyQ protein is visible at the synapse in elav>Q127-HA larvae. No synaptic overgrowth is 
detected in these animals. (J) NMJ from a control elav>GFP larvae. PolyQ proteins are labeled 
red (RFP-HDL2-Q138, RFP-HTT-Q138, or Q127-HA), anti-elav is shown in dark blue to label 
neuronal nuclei, and anti-HRP staining for labeling axons and synaptic terminals is cyan. Images 
A-C are single confocal planes, while images D-J are z-stacks. 
 
Figure 4. Addition of a nuclear import or export tag alters localization and toxicity of HDL2 
polyQ proteins. 
 (A) Schematic of GFP-HDL2-Q138attP2, the protein resulting from expression of the unmodified 
construct in the attP2 genetic docking site. The GFP label is shown in green and the polyQ 
stretch in magenta. (B) The HDL2 polyQ protein aggregates in the nucleus, but is also visible in 
the cytoplasm (arrowheads) of muscles in mef2>GFP-HDL2-Q138attP2 larvae. (C) mef2>GFP-
HDL2-Q138attP2 expression causes 3rd instar lethality. (D) Schematic of GFP-HDL2-Q138-
NLSattP2, the protein resulting from expression of the NLS-tagged construct. (E) The cytoplasmic 
polyQ protein contribution is completely absent in mef2>GFP-HDL2-Q138-NLSattP2 larvae, and 
the protein is found exclusively in the nucleus. (F) mef2>GFP-HDL2-Q138-NLSattP2 expression 
results in lethality during the 2nd instar stage. (G) Schematic of GFP-HDL2-Q138-NESattP2, the 
protein resulting from expression of the NES-tagged construct. (H) The nuclear polyQ protein 
contribution is completely ablated in mef2>GFP-HDL2-Q138-NESattP2 larvae. (I) Nuclear export 
of the polyQ protein suppresses lethality and mef2>GFP-HDL2-Q138-NESattP2 animals are adult 
viable. Images are single confocal planes.  
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Figure 5. Nuclear localization of HDL2-Q138attP2 causes a rough eye degenerative phenotype.  
(A) GMR>GFP animals express a soluble GFP under control of the GMR-GAL4 eye driver and 
were used as a control for GFP expression. (B) GMR>GFP-HDL2-Q138attP2 eyes appear normal.  
(C) Nuclear localization of the polyQ protein induces a rough eye phenotype in GMR>GFP-
HDL2-Q138-NLSattP2 animals. In addition to pigmentation defects, dark necrotic patches 
(arrowheads) are visible on the surface of the eye. (D) GMR>GFP-HDL2-Q138-NESattP2 eyes 
appear normal.  
 
Figure 6. Nuclear localization of HDL2-Q138 accelerates motor dysfunction onset and reduces 
lifespan, while nuclear export restores motor function and lifespan to control levels. 
(A) elav>GFP-HDL2-Q138attP2, elav>GFP-HDL2-Q138-NLSattP2 and elav>GFP-HDL2-Q138-
NESattP2 flies were briefly vortexed to knock them to the bottom of the vial, and their climbing 
ability (climb >2 cm in 30 sec) was compared to control elav flies at the indicated age. Nuclear 
localization flies have dramatically impaired motor function by 1 week. At three weeks, 
elav>HDL2-Q138attP2 flies fail to climb. For nuclear export flies, climbing ability remains 
indistinguishable from controls at all time points measured. For each time point, mean percent of 
flies climbing + SEM are: 1 day: control, 100% + 0; GFP-HDL2-Q138, 98%  + 2.2; GFP-
HDL2-Q138-NLS, 98% + 2.2; GFP-HDL2-Q138-NES, 96% + 2.9; not significant via ANOVA 
with Tukey’s post hoc test. 1 week: control, 96% + 2.9; GFP-HDL2-Q138, 100% + 0; GFP-
HDL2-Q138-NLS, 6% + 3.1, GFP-HDL2-Q138-NES, 96% + 2.7; GFP-HDL2-Q138-NLS 
climbing ability is significantly impaired compared to all other groups, p<0.0001 via ANOVA 
with Tukey’s post-hoc. 3 weeks: control, 97% + 2.9; GFP-HDL2-Q138, 0% + 0; GFP-HDL2-
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Q138-NES, 98% + 2.0; GFP-HDL2-Q138 climbing ability is significantly impaired compared to 
all other groups, p<0.0001 via ANOVA with Tukey’s post-hoc. 5 weeks: control, 83.71% + 6.4; 
GFP-HDL2-Q138-NES, 87.5% + 5.4; not significant via Student’s t test. (B) elav>GFP-HDL2-
Q138attP2, elav>GFP-HDL2-Q138-NLSattP2 and elav>GFP-HDL2-Q138-NESattP2 male flies were 
reared at 29°C and lifespan recorded. Neuronal expression of GFP-HDL2-Q138attP2 significantly 
reduces lifespan compared to control flies (median survival 28 versus 43 days, p<0.0001 via 
Mantel-Cox test). Nuclear localization significantly reduces lifespan compared to both controls 
and elav>GFP-HDL2-Q138attP2 animals (median survival 10 days, p<0.0001 via Mantel-Cox 
test). Nuclear export completely suppresses toxicity, and lifespan is not significantly different 
between control and elav>GFP-HDL2-Q138-NESattP2 flies (not significant via Mantel-Cox test).  
 
 
 
  
47 
 
 
Nucleus Cytoplasm 
Aggregates 
(large) 
Aggregates 
(small) Soluble 
Aggregates 
(large) 
Aggregates 
(small) Soluble 
HDL2-Q138 
   Neurons +++ ++ ++ - ++ - 
   Muscle +++ ++ ++ - ++ - 
   Epithelial cells - - + ++ ++ + 
HTT-Q138 
   Neurons - - - +++ ++ ++ 
   Muscle - - - ++ +++ + 
   Epithelial cells - - - +++ ++ ++ 
Q127 
   Neurons ++ ++ + - - - 
   Muscle ++ ++ ++ - + - 
   Epithelial cells + +++ ++ - - + 
 
Table 1. HDL2-Q138 localization is distinct from either HTT-Q138 or a pure polyQ tract in 
Drosophila.  
HTT-Q138 remains strictly cytoplasmic in Drosophila. Q127 alone does not localize to the 
cytoplasm in epithelial cells or neurons. Q127 is occasionally observed in the cytoplasm of 
muscle tissue, but only visible as small puncta. In contrast, HDL2-Q138 forms large nuclear 
inclusions in all cell types tested, except salivary gland epithelial cells, and also forms small 
aggregates or puncta in cytoplasm.   
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Abbreviations 
ANOVA, analysis of variance; DRPLA, dentatorubro-pallidoluysian atrophy; FTDALS1, 
frontotemporal dementia and/or amyotrophic lateral sclerosis 1; HD, Huntington disease; HTT, 
huntingtin; HDL2, Huntington disease-like 2; HRP, horseradish peroxidase; JPH3, junctophilin 
3; MJD, Machado-Joseph disease; DM1, mytotonic dystrophy 1; NMJ, neuromuscular junction; 
Q, glutamine; SEM, standard error of the mean; sca1, spinocerebellar ataxia 1; SCA2, 
spinocerebellar ataxia 2; SCA8, spinocerebellar ataxia 8; VNC, ventral nerve cord. 
 






